explore -WSS

explore

author：hotspot 2025-10-03 00:06:43 - browse：63

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Readout Newsletter: CAR

explore

WSS

Steward Health Care Massachusetts hospitals face fiscal disaster

Biden’s NIH nominee is languishing in Congress

Ebola: Gilead Sciences antiviral shows promise as new treatment

White House announces new plan to address the growing threat of xylazine in overdose crisis

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Biden declares emergency in flood

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Anesthesiologist group: stop taking Ozempic before surgery

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Supreme Court strikes down use of affirmative action

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Malaria cases in Florida and Texas: Here’s what you need to know

Pandemic and All Hazards Preparedness Act needs lean update

After affirmative action ruling, medical educators look to 'holistic review'

President Biden's budget: Here's what you might have missed

New air purifier tech could be key to improving indoor air quality

The aspartame in Diet Coke probably isn’t giving you cancer

focus

First U.S. drug developed to treat liver disease MASH is approved

President Biden's budget: Here's what you might have missed

Why scientists need input from humanists on sensitive research

Readout Newsletter: Bristol, Sangamo, Gilead, and more

How many hemophilia patients actually want gene therapy?

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Wikipedia

focus

explore

Wikipedia